Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing
Firm ‘Utterly Disagrees’ With CMA And Vows To Appeal Decision
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
